Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05225389 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects
A Phase 1 study, sponsored by Cognition Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05225389 is a Phase 1 study that has completed, run by Cognition Therapeutics. The registered enrollment target is 8 participants.
The verdict
NCT05225389, a Phase 1 study, has completed, sponsored by Cognition Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of \[C14\] CT1812
Interventions
- DRUG 300 mg [C14] CT1812
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-12-31 |
| Est. Completion | 2022-01-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05225389
The ClinicalTrials.gov registry entry for NCT05225389 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cognition Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 300 mg [C14] CT1812 is the first listed.
NCT05225389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05225389 about?
NCT05225389 is a clinical study titled "Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects". Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of \[C14\] CT1812
What is the current status of trial NCT05225389?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-12-31. Estimated completion is 2022-01-24.
What interventions are being tested in trial NCT05225389?
The interventions under investigation include: 300 mg [C14] CT1812 (DRUG).
Who is sponsoring clinical trial NCT05225389?
This trial is sponsored by Cognition Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.